Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 07, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Presents New Data in Primary Axillary Hyperhidrosis and Acne at American Academy of Dermatology 2017 Annual Meeting
March 03, 2017 08:23 ET
|
Dermira, Inc.
ORLANDO, Fla., March 03, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Cowen and Company 37th Annual Health Care Conference
March 02, 2017 16:05 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 02, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Prices $168.5 Million Public Offering of Common Stock
March 01, 2017 19:47 ET
|
Dermira, Inc.
MENLO PARK, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Announces Proposed Public Offering of Common Stock
February 28, 2017 17:13 ET
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
February 28, 2017 16:05 ET
|
Dermira, Inc.
-- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA ---- Management to host webcast and conference call today 4:30 p.m. ET /...
Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy Endpoint in Patients with Moderate-to-Severe Chronic Plaque Psoriasis
January 19, 2017 02:00 ET
|
Dermira, Inc.
CIMPACT results confirm data from two previously reported Phase 3 CIMZIA trialsSubmission of marketing applications to regulatory authorities expected in third quarter of 2017 BRUSSELS, Belgium and...
Dermira Provides Corporate Update
January 06, 2017 07:30 ET
|
Dermira, Inc.
Treatment period for DRM04 ARIDO trial completedPhase 3 acne clinical program for olumacostat glasaretil initiatedTopline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected...